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African  Americans  have  higher  prevalence  of  chronic  kid-
ney disease than non-Hispanic whites.1 Higher prevalence of 
hypertension and diabetes contribute to, but do not appear to 
fully explain, this disparity.2,3 Recently published national data 
confirm that blacks with both hypertension and prehyperten-
sion have higher rates of early kidney disease as indicated by 
microalbuminuria.4 The reasons for racial disparities in micro-
albuminuria are not known.
Emerging data link low serum vitamin D status to hyperten-
sion,5–8 albuminuria,9,10 and chronic renal disease.11,12 Potential 
mechanisms include stimulation of renin production,13 vascular 
smooth muscle proliferation,14 inflammation,13 thrombosis,15 
and impairment in endothelial function.16,17
Given unexplained racial disparities in microalbuminuria and 
well documented disparities in serum vitamin D status,18 we 
examined the hypothesis that low vitamin D might account for 
racial differences in albuminuria and also microalbuminuria.
Methods
Participants. We examined data from the National Health and 
Nutrition  Examination  Survey  (NHANES)  conducted  from 
2001–2006. Because of our focus on racial disparity in albu-
minuria, we confined our analysis to participants who self-
reported their ethnicity and race as non-Hispanic white or 
black.
Our sample included 7,651 adult participants (20 years and 
older)  who  participated  in  the  interview  and  examination 
and for whom blood pressure (BP), vitamin D status, urinary 
albumin, and creatinine values were available. We excluded 
participants  with  chronic  kidney  disease  (defined  as  esti-
mated glomerular filtration rate <60) and females who were 
pregnant (positive urine pregnancy test or self-reported preg-
nancy). In secondary analyses, we excluded participants with 
macroalbuminuria and also those with elevated parathyroid 
hormone (PTH) (>74 pg/ml).19
Blood pressure. BP was measured by physicians trained in assess-
ment using mercury sphygmomanometers and   appropriately 
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Background
National data show unexplained racial disparity in albuminuria. We 
assessed whether low serum vitamin D status contributes to racial 
disparity in albuminuria.
Methods
We examined the association between race and albuminuria (spot 
urinary albumin/creatinine ratio (Acr) ≥30) among non-Hispanic 
black and white nonpregnant adults who were free of renal 
impairment in the National Health and Nutrition examination Survey 
(NHANeS) from 2001–2006. We conducted analyses without and with 
serum 25(OH)D. We adjusted for age, sex, education level, smoking, 
body mass index (bMI), diabetes, diagnosis of hypertension, and use 
of antihypertensive medication.
results
Albuminuria was present in 10.0% of non-Hispanic blacks and 
6.6% in non-Hispanic whites. being black (odds ratio (Or) 1.46; 95% 
confidence interval (cI) 1.23–1.73) was independently associated 
with albuminuria. there was a graded, inverse association between 
25(OH)D level and albuminuria. Notably, the association between 
race and albuminuria was no longer significant (Or 1.19; 95% cI 
0.97–1.47) after accounting for participants’ serum 25(OH)D. Similar 
results were observed when participants with macroalbuminuria 
(Acr ≥300 mg/g) or elevated parathyroid hormone (>74 pg/ml) were 
excluded or when a continuous measure of 25(OH)D was substituted 
for the categorical measure. there were no interactions between 
race and vitamin D status though racial disparity in albuminuria was 
observed among participants with the highest 25(OH)D levels.
conclusion
Suboptimal vitamin D status may contribute to racial disparity in 
albuminuria. randomized controlled trials are needed to determine 
whether supplementation with vitamin analogues reduces risk for 
albuminuria or reduce racial disparity in this outcome.
Keywords: albuminuria; blood pressure; health status disparities; 
hypertension; vitamin D
American Journal of Hypertension, advance online publication 30 June 2011; 
doi:10.1038/ajh.2011.108
OpenAMERICAN JOURNAL OF HYPERTENSION | VOLUMe 24 NUMber 10 | OctOber 2011    1115
original contributions Vitamin D and Disparities in Albuminuria
sized arm cuffs.20–22 Readings were taken from participants 
while sitting after 5 min of rest. In determining mean BP, the 
first reading was used if only one measurement was obtained; 
the second reading was used if two readings were taken; and if 
more than two readings were taken, values were averaged over 
the last two when available.20–22
Participants  were  defined  as  having  treated  hypertension 
if  they  reported  taking  antihypertensive  medications  and 
untreated if they did not. Among untreated participants, BP 
was  classified  using  the  Seventh  Joint  National  Committee 
for  Prevention,  Detection,  Evaluation,  and  Treatment  of 
High BP (JNC-7) guidelines23: normal (systolic BP (SBP) was 
<120 mm Hg  and  the  diastolic  BP  (DBP)  was  <80 mm Hg), 
prehypertension  (SBP  of  120–139 mm Hg  or  DBP  of 
80–89 mm Hg), stage 1 hypertension (SBP of 140–159 mm Hg 
or DBP of 90–99 mm Hg), and stage 2 hypertension (SBP of 
≥160 mm Hg  or  DBP  of  ≥100 mm Hg).  Participants  taking 
antihypertensive drugs were considered to have controlled BP 
if their SBP was <140 mm Hg and their DBP was <90 mm Hg.
Vitamin D status. Serum 25(OH)D was measured using a radi-
oimmunoassay kit (DiaSorin, Stillwater, MN). The coefficient 
of variation for the years 2001–2006 ranged from 10–13% and 
the sensitivity for the 25(OH)D assay was 1.5 ng/ml).24 The 
serum 25(OH)D was adjusted for assay drift using methods 
recommended by the National Center for Health Statistics.25 
Although 1,25-dihydroxyvitamin D is the biologically active 
form of vitamin D, serum 25(OH)D is regarded as the best 
indicator of vitamin D status in individuals without kidney 
disease.26 We grouped 25(OH)D into the following categories: 
<25, 25–49, 50–74, 75–99, and ≥100 nmol/l.
Albuminuria.  The  untimed  urinary  albumin/creatinine  ratio 
(ACR) was classified as normal if ACR <30 mg/g, microalbu-
minuria if ACR is between 30–299 mg/g, and macroalbuminu-
ria if ACR ≥300 mg/g.27 In addition to predicting progression 
of renal disease, albuminuria (both micro and macro) predicts 
cardiovascular disease.28 The definition of ACR was based on 
the criteria of the National Kidney Foundation.29 The rationale 
for using ACR of 30 mg/g and above is based on evidence that 
microalbuminuria is a predictor of cardiovascular disease and 
end organ damage.30
In  our  primary  analysis,  we  combined  participants  with 
micro  and  macroalbuminuria  into  a  single  category:  albu-
minuria.  In  secondary  analyses,  we  focused  on  microalbu-
minuria  by  excluding  participants  with  macroalbuminuria 
from the analysis.
Race. Race and Hispanic ethnicity were assessed by self-report 
and were categorized as white (non-Hispanic) or black (non-
Hispanic).  Hispanics,  Asians,  Native  Americans,  and  par-
ticipants who self-identified with more than one race/ethnic 
group were not included in this study.
Control variables. We adjusted for potential confounding by 
including variables associated with albuminuria and vitamin D. 
These include age, sex, smoking, body mass index (BMI), BP, 
and diabetes.31–36 This represents a conservative approach since 
some of these variables may be affected by serum 25(OH)D 
levels.
Age  at  screening  was  grouped  into  categories  of  20–34, 
35–44, 45–54, 55–64, and those 65 years and older. Smoking 
status  was  defined  as  never  smoked,  current  smoker,  and 
former smoker. BMI was determined based on participants 
assessed weight (kg) and height (m) and categorized (<25.0; 
25.0–29.9; ≥30 kg/m2). Diabetes mellitus was defined by self-
report of physician diagnosis or current use of medications for 
diabetes mellitus.
Statistical analyses. Analyses were conducted with SUDAAN 
(version 10.01) and Stata (version 10.1, College Station, TX), 
adjusting for the complex survey design of NHANES to yield 
appropriate standard errors and population parameter esti-
mates. We examined the independent association of race with 
albuminuria (present or not) using logistic regression mod-
els. We compared the black-white differences in log odds of 
albuminuria before and after adjustment for 25(OH)D. We 
assessed interactions between 25(OH)D and race and between 
25(OH) D and BMI. We also conducted analyses stratified 
by serum 25(OH)D levels to examine possible differences in 
effects by race. Finally, we conducted several secondary analy-
ses. For this purpose, we repeated our analyses using micro-
albuminuria as a dependent variable, and excluding those with 
macroalbuminuria. We also repeated the analyses excluding 
those with elevated PTH and also using 25(OH)D as a con-
tinuous variable.
The model was checked for multicollinearity and no prob-
lem existed (all variance inflation factors <2). Since all of our 
independent variables are categorical, logit plots for linearity 
assessment were not needed. Independence is assumed due to 
the strict sampling methodology used by the NHANES group. 
Inspection of residuals did not reveal any influential outliers. 
In addition, a Hosmer–Lemeshow Goodness-of-fit χ2 statistic 
of 4.06, P = 0.8516 indicates that our model fits the data well.
results
Our  final  sample  included  7,651  non-Hispanic  blacks  and 
non-Hispanic whites, ages 20 years and older. Rates of miss-
ing data ranged from 0.01% for diabetes to 0.65% for estimated 
glomerular filtration rate. Albuminuria was missing for 3.5% 
of  participants.  Age,  BP,  and  smoking  were  independently 
associated with missing albuminuria data. Twenty five percent 
of blacks had 25(OH)D levels below 25 nmol/l compared to 
only 2% of whites.
The overall prevalence of albuminuria in the total sample 
was 7.0%. Its prevalence was 10.0% among blacks and 6.6% 
among whites. Table 1 compares the characteristics of partici-
pants with and without albuminuria. As expected, those with 
hypertension, older than 55, less education, obese, diabetes, 
and those with lower serum 25(OH)D levels had higher preva-
lence of albuminuria. Figure 1 compares 25(OH)D levels by 
race. Blacks clustered in the lowest levels of 25(OH)D.1116     OctOber 2011 | VOLUMe 24 NUMber 10 | AMERICAN JOURNAL OF HYPERTENSION
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Race is a significant risk factor for albuminuria (Table 2). 
Blacks had a 46% greater odds of albuminuria (odds ratio (OR) 
1.46; 95% confidence interval (CI) 1.23–1.73) than whites after 
adjusting  for  age,  sex,  education,  smoking,  BMI,  diabetes, 
BP, and hypertension treatment status. Other risk factors for 
albuminuria besides race included older age, diabetes, BP, and 
smoking.
When vitamin D categories were added to the model, it 
showed  a  graded,  inverse  relationship  with  albuminuria. 
The lowest level was associated with a 2.4 higher odds for 
albuminuria  compared  to  levels  >100 nmol/l.  Notably,  the 
association between race and albuminuria was no longer sta-
tistically significant after accounting for serum 25(OH)D (OR 
1.19; 95% CI 0.97–1.47). We observed similar effects when 
we used a continuous measure of 25(OH)D. Each nmol/l unit 
increase in 25(OH)D is associated with a 1% decreased odds 
for albuminuria (P < 0.01).
When we excluded participants with macroalbuminuria, we 
observed a similar relationship between race and microalbu-
minuria (OR 1.37; 95% CI 0.97–1.47) and a similar attenua-
tion with adjustment for 25(OH)D status (OR 1.11; (95% CI 
0.90–1.37). Similar results were also observed for the subsam-
ple (N = 2,375) where those with elevated PTH were excluded. 
Vitamin D status continued to show a graded inverse relation-
ship  with  albuminuria.  Similarly,  the  adjusted  OR  for  race 
declined from 1.56 to 1.41. However, CIs were wider and over-
lapped 1.0 for these analyses based on a smaller subsample 
(N = 2,355).
There was no statistically significant interactions between 
race and 25(OH)D (measured either as categorical or continu-
ous measure) or between race and BMI or BP. However, when 
we stratified the analyses by 25(OH)D level, blacks showed 
statistically  significant  higher  rates  of  albuminuria  only  at 
25(OH)D levels ≥75 nmol/l (P < 0.03). Among participants 
table 1 | characteristics of participants by presence of 
albuminuria
Albuminuria present
P 
value*
Yes  
(n = 716)
No  
(n = 6,935)
% (n)
Age (in years) <0.001
  20–34 3.7 (77) 96.3 (1,827)
  35–44 5.2 (86) 94.8 (1,306)
  45–54 6.5 (123) 93.5 (1,399)
  55–64 8.2 (115) 91.8 (986)
  65+ 16.3 (315) 83.7 (1,417)
Sex 0.04
  Male 6.3 (358) 93.7 (3,629)
  Female 7.7 (358) 92.3 (3,306)
Race <0.001
  White 6.6 (470) 93.4 (5,005)
  black 10.0 (246) 90.0 (1,930)
Education <0.001
  Less than high school 10.8 (207) 89.2 (1,203)
  High school 7.0 (165) 93.0 (1,825)
  More than high school 6.2 (344) 93.8 (3,897)
Smoking status <0.001
  current 7.7 (191) 92.3 (1,768)
  Former 8.5 (229) 91.5 (1,796)
  Never 5.9 (296) 94.1 (3,371)
Body mass index <0.001
  <25 6.2 (1,213) 93.8 (2,288)
  25–<30 5.6 (219) 94.4 (2,397)
  30+ 9.3 (284) 90.7 (2,250)
Diabetes <0.001
  Yes 25.1 (174) 74.9 (446)
  No 5.9 (542) 94.1 (6,489)
Blood pressure <0.001
  Normal blood pressure (untreated) 3.8 (110) 96.2 (2,498)
  Prehypertension 5.0 (124) 95.0 (1,916)
  Stage I hypertension 8.4 (66) 91.6 (580)
  Stage II hypertension 22.1 (63) 77.9 (157)
  treated, controlled hypertension 13.6 (353) 86.4 (1,784)
25(OH)D <0.001
  <25 nmol/l 12.2 (86) 87.8 (546)
  25–49 nmol/l 9.4 (278) 90.6 (2,138)
  50–74 nmol/l 6.2 (248) 93.8 (2,769)
  75–99 nmol/l 5.3 (83) 94.7 (1,185)
  >100 nmol/l 3.8 (21) 96.2 (297)
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with 25(OH)D levels ≥75 nmol/l, blacks showed higher crude 
prevalence than whites for albuminuria (13.3% vs. 4.9%). This 
effect persisted after adjusting for age, sex, education, smoking, 
BMI, BP, and diabetes (P < 0.03). However, only nine blacks 
were in this category, i.e., had 25(OH)D levels ≥75 nmol/l.
discussion
Reasons  for  disparity  in  albuminuria  between  blacks  and 
whites  are  not  fully  known.  Given  emerging  data  linking 
low serum vitamin D status to albuminuria,9,10 and develop-
ment of kidney disease,11,12 we examined the hypothesis that 
table 2 | logistic regression results for albuminuria with and without adjustment for Vitamin d
Risk factor Odds ratio
Lower  
95% limit
Upper  
95% limit P value* Odds ratio
Lower  
95% limit
Upper  
95% limit P value*
Age (in years)
  20–34 (referent) <0.001 <0.001
  35–44 1.24 0.86 1.78 1.24 0.86 1.77
  45–54 1.24 0.88 1.75 1.23 0.87 1.73
  55–64 1.32 0.89 1.97 1.31 0.88 1.95
  >65 2.64 1.85 3.76 2.61 1.83 3.73
Sex 0.08 0.12
  Male 0.83 0.67 1.02 0.85 0.69 1.05
  Female (referent)
Race <0.001 0.09
  White (referent)
  black 1.46 1.23 1.73 1.19 0.97 1.47
Education 0.20 0.20
  Less than high school 1.11 0.92 1.34 1.11 0.92 1.34
  High school 0.91 0.71 1.17 0.91 0.71 1.17
  More than high school (referent)
Smoking status <0.001 0.001
  current 1.72 1.41 2.1 1.65 1.35 2.02
  Former 1.26 1.05 1.51 1.26 1.05 1.51
  Never (referent)
Body mass index (kg/m2) 0.02 0.01
  <25 (referent)
  25–<30 0.73 0.57 0.95 0.71 0.55 0.92
  >30 1.08 0.81 1.43 0.99 0.74 1.33
Diabetes <0.001 <0.001
  Yes 3.27 2.48 4.32 3.25 2.48 4.26
  No (referent)
blood pressure group <0.001 <0.001
  Prehypertension 1.27 0.88 1.82 1.23 0.85 1.79
  Stage I hypertension 1.94 1.26 2.98 1.88 1.22 2.89
  Stage II hypertension 5.1 2.96 8.77 4.85 2.8 8.42
  treated, controlled hypertension 2.18 1.59 2.99 2.14 1.56 2.93
  Normal blood pressure, untreated (referent)
25(OH)D 0.01
  <25 nmol/l 2.41 1.27 4.59
  25–49 nmol/l 1.93 1.08 3.44
  50–74 nmol/l 1.47 0.85 2.55
  75–99 nmol/l 1.36 0.77 2.38
  >100 nmol/l (referent)
Logistic regression models for odds for albuminuria include age, sex, race, education, smoking status, body mass index, diabetes status, blood pressure group. *Based on F tests for 
significance of each term in the model. Based on χ2 tests for association.1118     OctOber 2011 | VOLUMe 24 NUMber 10 | AMERICAN JOURNAL OF HYPERTENSION
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vitamin D explains the association between race and albu-
minuria in a national sample of black and white adults. The 
findings reported in this study confirm our hypothesis that 
vitamin D contributes to the noted racial disparity in albu-
minuria.  Consistent  with  a  previous  report,4  we  observed 
significantly higher prevalence of albuminuria among non-
Hispanic  blacks  compared  with  non-Hispanic  whites.  We 
confirmed  previous  risk  factors  for  albuminuria  including 
older age, diabetes, BP, and smoking.31,32 Unexpectedly, the 
association of BMI and albuminuria was not statistically sig-
nificant. This could represent adjustment for factors in the 
causal path between BMI and albuminuria (e.g., diabetes and 
BP) and/or inadequate statistical power.
As reported in a previous study,9 we also observed a graded, 
inverse response between 25(OH)D levels and albuminuria. 
The lowest levels were associated with the highest prevalence 
of albuminuria. Our findings did not change when partici-
pants with macroalbuminuria or elevated PTH were excluded 
from the analyses.
Notably, when we adjusted for serum 25(OH)D, the rela-
tionship between race and albuminuria was no longer sta-
tistically significant. This is consistent with the hypothesis 
that 25(OH)D may partly mediate the association between 
race  and  albuminuria.  This  finding  is  broadly  consistent 
with a growing body of evidence suggesting that suboptimal 
vitamin D status is associated with vascular-related condi-
tions that are more prevalent among blacks. These include 
hypertension,37 diabetic nephropathy,10 peripheral vascular 
disease,38 kidney disease progressing to renal failure,11 and 
cardiovascular diseases39 and mortality.40
Endothelial  dysfunction  represents  a  possible  underlying 
mechanism of the effects of low vitamin D levels on albu-
minuria. Emerging data suggest that low vitamin D levels are 
associated with endothelial dysfunction and its correction alle-
viates this dysfunction.16,41–44 Albuminuria is associated with 
endothelial  dysfunction  including  impaired  vascular  func-
tion.45,46 Intriguingly, blacks have higher rates of endothelial 
dysfunction and small vessel disease than whites.47,48 Thus, it 
is conceivable that suboptimal vitamin D status among blacks 
might contribute to disparities in vascular-related conditions 
via  endothelial  dysfunction  as  manifested  in  part  through 
albuminuria.
Anthropological data suggest an evolutionary link between 
race and vitamin D consistent with an interaction between 
health  outcomes,  skin  color,  and  latitude  offering  further 
plausibility for this provocative hypothesis. Vitamin D levels 
in response to ultraviolet (UV) exposure from the sun may 
have played a pivotal role in the evolution of differences in 
skin pigment that emerged based on continental ancestry.49 
At low latitudes where UV exposure is high, dark skin pig-
ment from higher concentrations of melanin may protect the 
skin and circulating blood folate.50 As human populations 
moved north with less intense UV exposure, selection pres-
sures from vitamin D deficiency resulted in lighter skin pig-
ment. Reductions in UV exposure from northern residence 
and less exposure (more in door activity and greater use of 
sun protection) appear to be associated with rising preva-
lence of vitamin D deficiency.51 Consistent with the findings 
from our study sample, vitamin D levels are lowest among 
blacks.52
These findings are subject to several important caveats. First, 
because our findings are based on cross-sectional data, we can-
not determine the temporal relationship between 25(OH)D lev-
els and albuminuria. A previous study showed that low vitamin 
D levels at baseline predicts progression of kidney disease up 
to 16 years later.11 Such results are conceivable given the rela-
tive stability of serum 25(OH)D levels over time.53,54 Second, 
we cannot exclude the potential for confounding; it is possible 
that vitamin D is simply a marker for other factors associated 
with albuminuria. However, findings from a small randomized 
controlled trial suggest the possibility of a causal relationship, 
such that supplementation with the vitamin D analog, parical-
citol, reduced albuminuria among persons with chronic kidney 
disease.44 Third, the use of a single untimed ACR sample may 
underestimate albumin excretion among blacks (due to higher 
creatinine excretion).55,56 Thus, use of ACR to assess kidney dis-
ease provides a conservative estimate of this racial disparity. Last, 
although we did not observe a statistically significant interaction 
between race and 25(OH)D, we observed a statistically signifi-
cant effect of race and albuminuria only at 25(OH)D levels equal 
to or above 75 nmol/l. Whether this represents a chance finding 
or a differential effect by race, it has implications for the extent to 
which vitamin D status might contribute to this disparity. There 
is some evidence for vitamin D economy among blacks for bone 
turnover and formation, meaning that blacks maintain bone 
health at lower levels of vitamin D.57 Further study is needed to 
determine whether this holds for other outcomes. In particular, 
interventional trials are needed to both confirm a causal role of 
vitamin D status in albuminuria for both whites and blacks and 
determine whether there is a threshold effect.
In  conclusion,  vitamin  D  status  may  contribute  to  racial 
disparity  in  albuminuria.  Randomized  controlled  trials  are 
needed to determine whether supplementation with vitamin 
analogues will prevent albuminuria or mitigate racial disparity 
in albuminuria.
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